Details

Autor(en) / Beteiligte

• Mullard, Asher

Titel

Experimental obesity drug packs double punch to reduce weight

Ist Teil von

• Nature (London), 2024-05, Vol.629 (8013), p.733-734

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• "Iťs a strong paper," says Daniel Drucker, an endocrinologist at Mount Sinai Hospital in Toronto, Canada, who helped to unravel the role of gut hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) in obesity. The blockbuster weight-loss drugs semaglutide (sold as Wegovy) and tirzepatide (Zepbound) act by mimicking these hormones, binding to their receptors on neurons in the brain that control hunger pangs. Where the conjugate shone was in mice predosed with semaglutide: once the animals reached a weight-loss plateau with that drug, giving them the conjugate as an add-on treatment drove their body mass down further.